Tumor Suppressor Gene-Based Nanotherapy: From Test Tube to the Clinic

<table>IL-24 nanotherapy improves animal survival. Nude mice were injected with MeWo-GFP. Ten days after tumor cell injection mice were divided into four groups: group received no treatment; group 2 received IL-24 plasmid DNA; group 3 received empty nanocarrier; group 4 received IL-24-containing nanocarrier (50 <i>μ</i>g DNA). Treatment was twice a week and administered intravenously for six weeks. Mice were monitored for animal survival. Mice receiving IL-24-containing nanocarrier therapy showed increased survival compared to all other treatment groups.</table>

Journal of Drug Delivery

fig2

Figure 2

Figure 2: Tumor Suppressor Gene-Based Nanotherapy: From Test Tube to the Clinic 